HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICEATM

This article was originally published in The Rose Sheet

Executive Summary

No public comments were received on the "Addendum to the ICCVAM Evaluation of In Vitro Test Methods for Detecting Potential Endocrine Disruptors: Estrogen Receptor and Androgen Receptor Binding and Transcriptional Activation Assays," the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods states in a Sept. 28 Federal Register 1notice. The document is available on the NICEATM Web site. NTP had requested comments on the addendum when it was published in a March 16 Federal Register notice. The addendum proposed replacing four substances from a list proposed for validation of the screening methods (2"The Rose Sheet" March 20, 2006, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel